Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Blood blood.2024025834.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, Annemarie Munoz, Aradhika Dhawan, Nicole Chambers, Karen Fehn, Joel Victor, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Amit Verma, Mimi Kim, Ulrich Steidl, Eric J Feldman, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2023-188176

Published: 2023

Journal Articles

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Kateryna Fedorov, Alexander Sisto, Josette Kamel, Mark Forsberg, Kith Pradhan, Nishi Shah, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Kira Gritsman, Amit K. Verma, Eric J Feldman, Marina Y. Konopleva, Ioannis Mantzaris

Blood (2023) 142 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2023-180856

Published: 2023

Journal Articles

Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population

Lauren Laufer, Lemchukwu Amaeshi, Alex Sisto, Kateryna Fedorov, Rosmi Mathew, David Levitz, Ioannis Mantzaris, Noah Kornblum, Mendel Goldfinger, Alejandro Sica, Dennis L Cooper, Marina Y. Konopleva, Bruce Rapkin, Amit Verma, Aditi Shastri, Nishi Shah

Blood (2023) 142 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2023-186867

Published: 2023

Journal Articles

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Blood (2023) 142 (Supplement 1): 318.

https://doi.org/10.1182/blood-2023-179131

Published: 2023

Journal Articles

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

B. Hilda Ye, Eric Liu, Kith Pradhan, Erik Guillen, Urvi A Shah, Aditi Shastri, Gregoire Lauvau, Murali Janakiram, Alejandro Sica, Paul D. Kassner, Amit Verma

Blood (2023) 142 (Supplement 1): 6108.

https://doi.org/10.1182/blood-2023-191045

Published: 2023

Journal Articles

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Blood (2023) 142 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2023-186227

Published: 2023

Journal Articles

Inhibition of Toll-like Receptor 4 (TLR4) Promotes Erythroid and Myeloid Differentiation in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Ariel Fromowitz, Srinivas Aluri, Jesus D Gonzalez Lugo, Emma Rabinovich, Nandini Ramachandra, Sarah Aminov, Srabani Sahu, Shanisha Gordon Mitchell, Ritesh Aggarwal, Opeyemi Ajibade, Milagros Carbajal, Kith Pradhan, Andrea Pellagatti, Jacqueline Boultwood, Aditi Shastri, Rongbao Zhao, Amit K. Verma

Blood (2023) 142 (Supplement 1): 5615.

https://doi.org/10.1182/blood-2023-182059

Published: 2023

Journal Articles

The Prevalence and Mutational Spectrum of Clonal Hematopoiesis in Diverse Populations in New York City

Varun Gupta, Mariko Isshiki, Anna Skwarska, Kith Pradhan, Amit K. Verma, Marina Y. Konopleva, Aditi Shastri, Srilakshmi Raj

Blood (2023) 142 (Supplement 1): 5604.

https://doi.org/10.1182/blood-2023-180973

Published: 2023

Journal Articles

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Shivani Handa, Namrata Sonia Chandhok, Sudhamsh Reddy Desai, Asem Berkalieva, Erin Moshier, Douglas Tremblay, Lewis R. Silverman, Trent Wang, Uroosa Ibrahim, Aditi Shastri, Jonathan Feld

Blood (2023) 142 (Supplement 1): 3239.

https://doi.org/10.1182/blood-2023-190346

Published: 2023

Journal Articles

Exposure to Fine Particulate Matter (PM2.5) Is Associated with Worse Multiple Myeloma Outcomes in a Large, Urban, Multi-Ethnic Cohort

Michael Wysota, Sarah Jacobs, Kith Pradhan, Joel Rosiene, Charles Hall, George Downward, Yocheved Halberstam, Nishi Shah, Dean Hosgood, Aditi Shastri

Blood (2023) 142 (Supplement 1): 531.

https://doi.org/10.1182/blood-2023-186937

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

Blood (2023) 142 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2023-182289

Published: 2023

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Lemchukwu Amaeshi, Alex Sisto, Lauren Laufer, Kateryna Fedorov, Rosmi Mathew, David Levitz, Ioannis Mantzaris, Noah Kornblum, Mendel Goldfinger, Alejandro Sica, Dennis L Cooper, Marina Y. Konopleva, Bruce Rapkin, Amit Verma, Aditi Shastri, Nishi Shah

Blood (2023) 142 (Supplement 1): 7397.

https://doi.org/10.1182/blood-2023-188024

Published: 2023

Journal Articles

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML

Nandini Ramachandra, Charan Thej Reddy Vegivinti, Srabani Sahu, Bianca Rivera, Sarah Aminov, Ariel Fromowitz, Jinghang Zhang, Fnu Aodengtuya, Kith Pradhan, Rongbao Zhao, Leya Schwartz, Victor Thiruthuvanathan, Rahul Sanawar, Emma Rabinovich, Opeyemi Ajibade, Aditi Shastri, Michael Lahn, Amit K. Verma

Blood (2023) 142 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2023-179921

Published: 2023

Journal Articles

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Josette M Kamel, Mendel Goldfinger, Jiani Chai, Jui Choudhuri, Marina Y. Konopleva, Eric J Feldman, Ioannis Mantzaris, Dennis L Cooper, Aditi Shastri, Nishi Shah, Noah Kornblum, Kira Gritsman, Alejandro Sica, Yanhua Wang, Xuejun Tian, Amit Verma, Swati Goel

Blood (2023) 142 (Supplement 1): 6050.

https://doi.org/10.1182/blood-2023-188243

Published: 2023

Journal Articles

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Jiani Chai, Jui Choudhuri, Qing Wang, Yanan Fang, Yang Shi, Wa Shen, Swati Goel, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Nishi Shah, Kira Gritsman, Marina Konopleva, Noah Kornblum, Amit Verma, Mendel Goldfinger, Yanhua Wang, Xuejun Tian

Blood (2022) 140 (Supplement 1): 6256–6257.

https://doi.org/10.1182/blood-2022-162857

Published: 2022

NARROW

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Inhibition of Toll-like Receptor 4 (TLR4) Promotes Erythroid and Myeloid Differentiation in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

The Prevalence and Mutational Spectrum of Clonal Hematopoiesis in Diverse Populations in New York City

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Exposure to Fine Particulate Matter (PM2.5) Is Associated with Worse Multiple Myeloma Outcomes in a Large, Urban, Multi-Ethnic Cohort

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only